| Identification | Back Directory | [Name]
4-[[(4-Methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]methyl]-N-[2-[[[(2-thienylmethyl)amino]carbonyl]amino]ethyl]benzamide | [CAS]
2614161-13-4 | [Synonyms]
MyoMed 205 4-[[(4-Methyl-2-oxo-2H-1-benzopyran-7-yl)oxy]methyl]-N-[2-[[[(2-thienylmethyl)amino]carbonyl]amino]ethyl]benzamide | [Molecular Formula]
C26H25N3O5S | [MOL File]
2614161-13-4.mol | [Molecular Weight]
491.56 |
| Chemical Properties | Back Directory | [Boiling point ]
812.8±65.0 °C(Predicted) | [density ]
1.312±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
13.27±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MyoMed-205 is an inhibitor targeting the activity of MuRF1. MyoMed-205 prevents early diaphragmatic systolic dysfunction and atrophy due to unilateral diaphragmatic nerve denervation 12 hours later. MyoMed-205 reduces ubiquitination and subsequent proteasomal degradation of muscle proteins by inhibiting MuRF1 activity. MyoMed-205 increases levels of a protein that phosphorylates Akt (ser473), an important signaling molecule for muscle growth and maintenance. MyoMed-205 can be used to study and treat diaphragmatic dysfunction and atrophy (DIDD) caused by early apraxia, especially in clinical situations such as diaphragmatic paralysis or mechanical ventilation[1]. | [References]
[1] Ribeiro F, et al. Small-Molecule Inhibition of MuRF1 Prevents Early Disuse-Induced Diaphragmatic Dysfunction and Atrophy[J]. International Journal of Molecular Sciences, 2023, 24(4): 3637. DOI:10.3390/ijms24043637 |
|
|